Neurosurgery News and Research

RSS

UT Southwestern Medical Center tops best hospital rankings for Dallas-Fort Worth

UT Southwestern Medical Center ranked as the best hospital in Dallas-Fort Worth in the newly expanded U.S. News & World Report's America's Best Hospitals rankings for 52 metropolitan areas.

30 Mar 2011

Multiple drugs bonded to 'transport vehicle' bypass healthy cells to attack breast cancer from inside

Researchers at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute have employed a strategy using a mouse model to target important mechanisms inside the most challenging breast cancer cells. Earlier studies at Cedars-Sinai found a similar approach effective in attacking malignant brain tumor targets.

30 Mar 2011

Findings conflict with traditional view of how epileptic seizures begin

The first study to examine the activity of hundreds of individual human brain cells during seizures has found that seizures begin with extremely diverse neuronal activity, contrary to the classic view that they are characterized by massively synchronized activity.

28 Mar 2011

FDA approves humanitarian device exemption for Elana Surgical Kit in cerebral bypass

Dutch medical device manufacturer, Elana bv, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for a humanitarian device exemption (HDE), enabling a lifesaving cerebral bypass. Elana bv is a corporate spin-off from the University Medical Centre Utrecht, the Netherlands.

25 Mar 2011

Stemedica begins allogeneic mesenchymal stem cell Phase I/II trial in patients with ischemic stroke

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that its specially formulated ischemic adult allogeneic mesenchymal stem cells have been successfully used to treat the first patient in an ischemic stroke study conducted at the University of California, San Diego.

25 Mar 2011

UC Berkeley, UCSF partner to help develop neural prostheses for brain repair

Neuroscientists and engineers at UCSF and UC Berkeley have joined forces to help pioneer a new frontier of brain repair - the development of devices that would allow patients with such conditions as stroke, spinal cord injury, traumatic brain injury and Lou Gehrig's disease to control prosthetics through thoughts alone.

25 Mar 2011

Quantum dots allow stem cell therapy monitoring for brain injury

A new technique using "quantum dots" produced through nanotechnology is a promising approach to monitoring the effects of stem cell therapies for stroke and other types of brain damage, reports the April issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

25 Mar 2011

FDA clears MASEP Infini's gamma ray neurosurgery system

MASEP Infini, an innovator in global medical technology, today announced 510(k) clearance from the U.S. Food and Drug Administration of its new Infini gamma ray neurosurgery system with patented Independent Beam Switch Control with Programmable Arcs, automated collimator exchange and three-dimensional patient positioning, and MASEP Infini's proven Rotary Focusing technology.

24 Mar 2011

$Cancer patients with spinal fractures can benefit from Kyphon Balloon Kyphoplasty$

Cancer patients with spinal fractures can benefit from Kyphon Balloon Kyphoplasty

Medtronic of Canada Ltd. today announced the results of the first randomized, controlled trial comparing Kyphon Balloon Kyphoplasty with non-surgical care in treating spinal fractures in cancer patients.

23 Mar 2011

LDR submits two-level Mobi-C cervical artificial disc PMA to the FDA

LDR, a privately held medical device company offering innovative spinal implants for both non-fusion and fusion applications, announced the March 11 submission of its two-level Mobi-C cervical artificial disc PMA to the FDA. LDR is one of only two companies to have completed a two-level randomized IDE trial with two-year follow up, and is the first to submit its results.

23 Mar 2011

IASIS enters definitive agreement to purchase 78.2% interest in St. Joseph Medical Center

IASIS Healthcare LLC today announced that it has entered into a definitive agreement to purchase a 78.2% interest in St. Joseph Medical Center, a 792-bed facility in downtown Houston, Texas.

19 Mar 2011

Medical Facilities fourth quarter consolidated facility service revenue increases 10.9% to $64.4 million

Medical Facilities Corporation, today reported its financial results for the three- and twelve-month periods ended December 31, 2010.

18 Mar 2011

Major clinical studies for heart disease, stroke fail to consider participant's ethnicity

Major clinical studies that evaluate prevention strategies for heart disease and stroke fail to consider a participant's ethnicity, a factor that can more than double the rate of death in some groups, according to research led by St. Michael's Dr. Joel Ray.

18 Mar 2011

Individualized dentritic cell vaccine may increase survival time in patients with glioblastoma

A dendritic cell vaccine personalized for each individual based on the patient's own tumor may increase median survival time in those with a deadly form of brain cancer called glioblastoma, an early phase study at UCLA's Jonsson Comprehensive Cancer Center has found.

18 Mar 2011

St. Michael's receives $5 million McCain donation for therapeutic endoscopy program

Wallace and Margaret McCain have donated $5 million to St. Michael's Hospital for its therapeutic endoscopy program.

18 Mar 2011

Gene therapy holds promise for Parkinson's treatment

A first-of-its-kind study of gene therapy in the treatment of Parkinson's disease determined that half of all patients who received the treatment had "clinically meaningful improvements" of their symptoms within six months of surgery.

17 Mar 2011

Personalized dendritic cell vaccine may increase median survival in mesenchymal glioblastoma patients

17 Mar 2011

Naltrexone may be effective in women with specific genetic variation

Results from a new study suggest that one of the most prescribed medications for alcohol dependence may be more effective in some people. Preliminary results show that naltrexone, one of the only medications approved for treating people with alcohol abuse problems, may only be effective in women and those with a specific genetic variation.

17 Mar 2011

The Lancet Neurology publishes Neurologix NLX-P101 Phase 2 trial results against PD

Neurologix, Inc., announced today that the results of the Company's Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease were published in an online-first edition of The Lancet Neurology.

17 Mar 2011

Results from first successful phase 2 trial of gene therapy for Parkinson's or any neurologic disorder

A gene therapy called NLX-P101 dramatically reduces movement impairment in Parkinson's patients, according to results of a Phase 2 study published today in the journal Lancet Neurology. The approach introduces a gene into the brain to normalize chemical signaling.

16 Mar 2011

Neurosurgery News and Research

UT Southwestern Medical Center tops best hospital rankings for Dallas-Fort Worth

Multiple drugs bonded to 'transport vehicle' bypass healthy cells to attack breast cancer from inside

Findings conflict with traditional view of how epileptic seizures begin

FDA approves humanitarian device exemption for Elana Surgical Kit in cerebral bypass

Stemedica begins allogeneic mesenchymal stem cell Phase I/II trial in patients with ischemic stroke

UC Berkeley, UCSF partner to help develop neural prostheses for brain repair

Quantum dots allow stem cell therapy monitoring for brain injury

FDA clears MASEP Infini's gamma ray neurosurgery system

Cancer patients with spinal fractures can benefit from Kyphon Balloon Kyphoplasty

LDR submits two-level Mobi-C cervical artificial disc PMA to the FDA

IASIS enters definitive agreement to purchase 78.2% interest in St. Joseph Medical Center

Medical Facilities fourth quarter consolidated facility service revenue increases 10.9% to $64.4 million

Major clinical studies for heart disease, stroke fail to consider participant's ethnicity

Individualized dentritic cell vaccine may increase survival time in patients with glioblastoma

St. Michael's receives $5 million McCain donation for therapeutic endoscopy program

Gene therapy holds promise for Parkinson's treatment

Personalized dendritic cell vaccine may increase median survival in mesenchymal glioblastoma patients

Naltrexone may be effective in women with specific genetic variation

The Lancet Neurology publishes Neurologix NLX-P101 Phase 2 trial results against PD

Results from first successful phase 2 trial of gene therapy for Parkinson's or any neurologic disorder

Neuroscience - Second Edition eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News